Prohibits excessive increases in prices charged for essential off-patent and generic prescription drugs and biological products.
Impact
If enacted, A4184 would significantly impact state laws governing pharmaceutical pricing. The bill mandates that manufacturers and wholesale distributors cannot increase prices excessively, specifically when no viable alternatives exist for consumers to purchase critical medications. Violations of this law could result in significant penalties, with each act of price gouging resulting in a civil penalty of up to $10,000. Regulatory measures would also include monitoring wholesale acquisition costs to ensure compliance and protect consumers, especially those reliant on healthcare programs like Medicaid.
Summary
Assembly Bill A4184, introduced by Assemblywoman Carol A. Murphy, aims to prohibit excessive price increases on essential off-patent and generic prescription drugs and biological products. The bill addresses a growing concern about price gouging in the pharmaceutical industry, particularly affecting consumers who rely on these essential medications. The legislation defines 'price gouging' as an increase in prices that is excessive and not justified by production costs or improvements in public health access. This bill is expected to promote a more equitable pricing model in the emergency of essential medicines.
Contention
While the bill receives considerable support for addressing high drug prices, there are potential pushbacks from pharmaceutical companies and wholesalers who may argue that restrictions on pricing can interfere with market dynamics and discourage investment in drug development. The requirement for manufacturers to justify price increases to the Attorney General could also raise concerns about confidentiality and the potential chilling effect on pricing strategies. Thus, while the bill seeks to enhance consumer protection, the discussion around it highlights a need for balancing regulation with industry viability.